ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brand, P.
Right arrow Articles by Scheuch, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brand, P.
Right arrow Articles by Scheuch, G.
Eur Respir J 2003; 22:263-267
Copyright ©ERS Journals Ltd 2003

Peripheral deposition of {alpha}1-protease inhibitor using commercial inhalation devices

P. Brand1, H. Beckmann2, M. Maas Enriquez2, T. Meyer3, B. Müllinger3, K. Sommerer3, N. Weber1, T. Weuthen3 and G. Scheuch3

1 Clinical Research Group "Aerosols in Medicine" of the GSF-Institute for Inhalation Biology and the Asklepios Clinic for Respiratory Medicine, 2 Bayer Vital GmbH, Leverkusen and 3 Inamed-Intelligent Aerosol Medicine GmbH, Gauting, Germany

CORRESPONDENCE: P. Brand, GSF-Institute for Inhalation Biology, Robert-Koch-Allee 29, D-82131, Gauting, Germany. Fax: 49 8989323711. E-mail: brand@inamed.de

Keywords: Inhalation, inhalation devices, {alpha}1-protease inhibitor, replacement therapy

Received: December 19, 2002
Accepted March 14, 2003

This study was supported by Bayer Corporation, Research Triangle Park, NC, USA.

Patients with hereditary {alpha}1-proteinase inhibitor ({alpha}1-PI) deficiency are at risk of developing lung emphysema. To prevent the development of this disease, {alpha}1-PI replacement therapy via inhalation may be a more convenient and effective therapy than the intravenous administration of the drug.

In order to optimise this treatment approach, lung deposition of inhaled radiolabelled {alpha}1-PI (Prolastin®) was studied using four different commercial inhalation devices (PARI-LC Star®, HaloLite®, and AKITA® system in combination with LC Star® and Sidestream®) in six patients with {alpha}1-PI deficiency and mild-to-severe chronic obstructive pulmonary disease.

The time required to deposit 50 mg of the Prolastin® (5% solution) in the lung periphery was used as a measure for the efficiency of delivery. The time was calculated from measurements of total and peripheral lung deposition of the radiolabelled {alpha}1-PI. This time was shortest for the AKITA® system (18–24 min) and significantly higher for the PARI-LC Star® (44 min) and the HaloLite® (100 min).

The higher efficiency of drug delivery using the AKITA® system is due to the fact that this device controls breathing patterns, which are optimised for each patient individually.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. Griese, P. Latzin, M. Kappler, K. Weckerle, T. Heinzlmaier, T. Bernhardt, and D. Hartl
{alpha}1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
Eur. Respir. J., February 1, 2007; 29(2): 240 - 250.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the European Respiratory Society.